Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationGastroenterologyIssue 729

Potential Treatment for Symptoms of Diabetic Gastroparesis

In a phase 2 trial, patients with diabetic gastroparesis displayed increased gastric emptying and improvement in vomiting after treatment with relamorelin-131.... 

Advertisement

In a phase 2 trial, researchers randomly assigned 204 patients with diabetic gastroparesis (DG) (mean age, 55.1 years; 32.3% men) into a double blind, placebo-controlled study for 28 days. Patients were enlisted to take two daily injections of relamorelin-131 10 mcg (RM-131; Rhythm) before an evening meal (n=67), RM-131 10 mcg before breakfast and an evening meal (n=68) or placebo (n=69). Patients' daily symptoms were recorded on a 0-10 scale, and a gastric emptying breath test (GEBT) was performed at baseline and on day 28.

Patients who received RM-131 before breakfast and evening meals showed accelerated GE (P<.03), the study's primary endpoint, and an improvement in vomiting (P=.033), compared with placebo patients. Results for patients who took RM-131 only before evening meals were not presented.

Post-hoc analysis of 119 patients with baseline vomiting revealed that RM-131 had a positive effect on GE, and overall weekly vomiting was reduced by 63%. This subgroup also exhibited improvements in nausea, bloating, early satiety and abdominal pain, compared with the placebo arm (P<.043). Few adverse events occurred, according to the study.

Anthony Lembo, MD, gastroenterologist at Beth Israel Deaconess Medical Center, Boston, stated that, "In summary, RM-131 10 mcg twice daily showed more efficacy than once daily." "In post-hoc analysis in the subgroup of patients, RM-131 10 mcg twice daily is effective in all endpoints. There were no safety concerns seen in the studies."

Practice Pearls:
  • Selective ghrelin pentapeptide relamorelin-131, showed positive results in treating gastroparesis
  • The results of this study are preliminary and no conclusions should be made until it has been reviewed and published.

Presented at: Digestive Disease Week 2014; May 3-6; Chicago. Lembo A. #929a. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  MedicationGastroenterologyIssue 729

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
Important Advances in Type 1 Diabetes Research
Posted June 25, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Would you be interested in a urine test strip product that measures microalbumin and creatinine levels to determine kidney failure risk in your patients?

CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75